Identifying copyright holders and response times are major challenges in COA licensing, causing delays in clinical trials. Clear documentation of copyright ownership and standardized response times ...
Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...
In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...
Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...
In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...
In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...
So having a representative population is really important. One part of that is being able to enroll more patients in the ...
Real-world adverse events are rarely monocausal. They emerge from the interaction of drug exposure, comorbid conditions, physiological states, concomitant medications, and patient-specific ...
BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...
The merger enhances Verana Health's data capabilities across oncology, ophthalmology, urology, and neurology, supporting clinical research and regulatory decision-making. Integration of COTA's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback